Director Clinical-Translational Science
AdvanCell
Director Clinical-Translational Science
AdvanCell
Manufactures Lead-212 for targeted alpha therapy
Biobanking and Research Operations
Note: Some samples require immediate processing upon receipt at TRI, which may occasionally require work outside standard hours.
Clinical Translational Research
Scientific Leadership and Collaboration
Data, Systems and Quality Oversight
Laboratory Operations and Infrastructure
Continuous Improvement and Innovation
Compliance, Governance and Documentation
AdvanCell develops radiopharmaceuticals for targeted alpha therapy, using Lead-212 and an on-demand Alpha Isotope Generator to produce the isotope daily. Its core product ADVC-001 targets PSMA to treat metastatic castration-resistant prostate cancer, evaluated in the multicenter TheraPb Phase I/II trial, while the company also pipelines other cancer therapies. The approach combines isotope production, drug manufacturing, and clinical development in a vertically integrated model to ensure reliable supply and faster development. Its goal is to speed patient access to radiopharmaceutical treatments by expanding its portfolio through collaborations, including a strategic partnership with Eli Lilly, and advancing clinical trials.
Explore more opportunities at AdvanCell